{
  "report_rows": [
    {
      "kpi": "Q2 revenue",
      "prediction": "BEAT",
      "answer": "pred ~$1.218B vs. cons $1.205B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.04 vs. cons $3.95",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 CAG Diagnostics recurring organic revenue growth",
      "prediction": "BEAT",
      "answer": "pred ~10.1% vs. cons 9.5%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Full-year revenue guidance midpoint",
      "prediction": "BETTER",
      "answer": "guide ~$4.740B vs. cons $4.720B (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Full-year CAG Diagnostics recurring organic revenue growth midpoint",
      "prediction": "BETTER",
      "answer": "guide ~9.8% vs. cons 9.7% (FY2026)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Full-year diluted EPS guidance midpoint",
      "prediction": "BETTER",
      "answer": "guide ~$14.82 vs. cons $14.68 (FY2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 4.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 6.2,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "The projected FY2026 EPS guide midpoint of ~$14.82 vs. consensus $14.68 implies that the expected Q2 EPS beat of ~$4.04 vs. $3.95 is not merely absorbed by weaker out-period assumptions. Modest second-half revenue and recurring-growth upgrades should support upward estimate revisions after the initial reaction.",
  "day5_confidence": "MEDIUM"
}